XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Helen Boudreau [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On March 5, 2024, Helen Boudreau, a member of the Company’s Board of Directors, entered into a Rule 10b5-1 trading arrangement (as defined in Item 408 of Regulation S-K). Ms. Boudreau’s plan provides for the potential sale of up to 60,000 shares of the Company’s common stock issuable upon the exercise of options. The plan terminates on the earlier of (i) September 30, 2024, (ii) the first date on which all trades have been executed or all trading orders relating to such trades set forth in the plan have expired or (iii) such time as the plan is otherwise terminated according to its terms.
Name Helen Boudreau
Title member of the Company’s Board of Directors
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 5, 2024
Arrangement Duration 209 days
Aggregate Available 60,000
Casi DeYoung [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On March 6, 2024, Casi DeYoung, the Company’s Chief Business Officer, entered into a Rule 10b5-1 trading arrangement. Ms. DeYoung’s plan provides for the potential sale of up to (i) 32,082 shares of the Company’s common stock, (ii) 3,500 shares of restricted common stock issuable upon the vesting of such shares and (iii) 30,000 shares of the Company’s common stock issuable upon the exercise of options. The plan terminates on the earlier of (i) March 1, 2025, (ii) the first date on which all trades have been executed or all trading orders relating to such trades set forth in the plan have expired or (iii) such time as the plan is otherwise terminated according to its terms.
Name Casi DeYoung
Title Chief Business Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 6, 2024
Arrangement Duration 360 days
Lini Pandite [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement
On March 12, 2024, Lini Pandite, the Company’s Chief Medical Officer, modified an existing Rule 10b5-1 trading arrangement, originally adopted on April 3, 2023, to modify (i) the sale periods, (ii) the minimum prices at which sales may be made and (iii) the termination date under the plan. The original plan provided for the potential sale of up to 83,514 shares of the Company’s common stock. Prior to its modification, no shares of common stock were sold pursuant to the original plan. The modified plan provides for the potential sale of up to 83,514 shares of the Company’s common stock and terminates on the earlier of (A) May 30, 2025, (B) the completion of the sale of the maximum number of shares under the plan or (C) such time as the plan is otherwise terminated according to its terms.
Name Lini Pandite
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date March 12, 2024
Arrangement Duration 444 days
Aggregate Available 83,514
Casi DeYoung Trading Arrangement, Common Stock [Member] | Casi DeYoung [Member]  
Trading Arrangements, by Individual  
Aggregate Available 32,082
Casi DeYoung Trading Arrangement, Restricted Stock [Member] | Casi DeYoung [Member]  
Trading Arrangements, by Individual  
Aggregate Available 3,500
Casi DeYoung Trading Arrangement, Stock Options [Member] | Casi DeYoung [Member]  
Trading Arrangements, by Individual  
Aggregate Available 30,000